ArticleAnnals of clinical microbiology and antimicrobials2016
Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional study.
Article in Annals of clinical microbiology and antimicrobials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.
- Hospital-acquired and zoonotic bacteria from a veterinary hospital and their associated antimicrobial-susceptibility profiles: A systematic review.Frontiers in veterinary science · 2022Pooled it
- Continuous versus intermittent vancomycin infusions in critically ill children with gram-positive bacterial infections: a randomized controlled trial.BMC infectious diseases · 2026Trial
- Whole-genome sequences ofMicrobiology resource announcements · 2026Article
- Sequential Screening of Lactic Acid Bacteria from Fermented Sour Bamboo Shoots and Their Effects on Patient-Derived Fecal Microbiota In Vitro.Microorganisms · 2026Article
- Emerging role of essential oil biomolecules: a sustainable therapeutic approach to combat microbial pathogens.Archives of microbiology · 2026Review
- Global in silico genomic epidemiology of tetracycline resistance in Staphylococcus aureus: one health dynamics and genotype-phenotype associations.Molecular genetics and genomics : MGG · 2026Article
- Clinical Relevance of Antimicrobial Susceptibility Testing Methods in Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Biocontrol Potential of Selected Lamiaceae Species AgainstTheScientificWorldJournal · 2026Article
- Bacterial diversity and antibiotic susceptibility profile of the isolates from public vehicles in Butwal Sub-Metropolitan City, Rupandehi, Nepal.PLOS global public health · 2026Article
- Research on the application of a high-throughput fully automated bacterial growth curve monitor for screening natural antibacterial compounds.BMC microbiology · 2025Article
- Epidemiological and clinical characteristics of bacterial co-detection in respiratory syncytial virus-positive children in Wenzhou, China, 2021 to 2023.BMC infectious diseases · 2025Observational
- Synergistic Artemisia monosperma with royal jelly: antibacterial, antioxidant, antibiofilm, and anti-Alzheimer assay.AMB Express · 2025Article
- Geo-Temporal Variation in the Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2025Article
- Antimicrobial Susceptibility ofMicroorganisms · 2025Article
- Occurrence, Risk Factors, and Antibiotic Resistance Patterns ofBioMed research international · 2025Article
- Epidemiology, risk factors, and antimicrobial resistance of nosocomial infections in the intensive care unit trauma patients: A cross-sectional study.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Article
- Encapsulation of propolis extracted with methylal in the chitosan nanoparticles and its antibacterial and cell cytotoxicity studies.BMC complementary medicine and therapies · 2024Article
- Vertical Transmission of Group BInternational journal of microbiology · 2024Article
- Antibiotic susceptibility and phenotypic profile ofSAGE open medicine · 2024Article
- Antibacterial and Photocatalytic Activity of ZnO/Au and ZnO/Ag Nanocomposites.International journal of molecular sciences · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Clinical Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines are the most popular breakpoint guidelines used in antimicrobial susceptibility testing worldwide. The EUCAST guidelines are freely available to users while CLSI is available for non-members as a package of three documents for US $500 annually. This is prohibitive for clinical microbiology laboratories in resource poor settings. We set out to compare antibiotic susceptibility determined by the two guidelines to determine whether adoption of EUCAST guidelines would significantly affect our susceptibility patterns.
methodsWe reviewed minimum inhibitory concentrations (MIC) of various antibiotics routinely reported for Escherichia coli (E. coli), Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) isolates from an automated microbiology identification system (VITEK-2) at the Aga Khan University Hospital Nairobi's Pathology department. These MICs were then analyzed using both CLSI 2015 and EUCAST 2015 guidelines and classified as resistant, intermediate or susceptible. We compared the susceptibility and agreement between the CLSI and EUCAST categorizations.
resultsSusceptibility data from a total of 5165 E. coli, 1103 S. aureus and 532 P. aeruginosa isolates were included. The concordance rates of the two guidelines for E. coli, S. aureus and P. aeruginosa ranged from 78.2 to 100 %, 94.6 to 100 % and 89.1 to 95.5 % respectively. The kappa statistics for E. coli MICs revealed perfect agreement between CLSI and EUCAST for cefotaxime, ceftriaxone and trimethoprim-sulfamethoxazole, almost perfect agreement for ampicillin, ciprofloxacin, cefuroxime, gentamicin and ceftazidime, substantial agreement for meropenem, moderate agreement for cefepime and amoxicillin-clavulanate, fair agreement for nitrofurantoin and poor agreement for amikacin. For S. aureus the kappa statistics revealed perfect agreement for penicillin, trimethoprim-sulfamethoxazole, levofloxacin, oxacillin, linezolid and vancomycin, almost perfect agreement for clindamycin, erythromycin and tetracycline and moderate agreement for gentamicin. For P. aeruginosa the kappa analysis revealed moderate to almost perfect agreement for all the anti-pseudomonal antibiotics.
conclusionThe results show comparable antibiotic susceptibility patterns between CLSI and EUCAST breakpoints. Given that EUCAST guidelines are freely available, it makes it easier for laboratories in resource poor settings to have an updated and readily available reference for interpreting antibiotic susceptibilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.